Last reviewed · How we verify

NAI — Competitive Intelligence Brief

NAI (NAI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: capsid-binding antiviral. Area: Gastroenterology.

marketed capsid-binding antiviral norovirus capsid protein Gastroenterology Biologic Live · refreshed every 30 min

Target snapshot

NAI (NAI) — Glenn J. Hanna. NAI is an antiviral medication that inhibits the replication of the norovirus.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NAI TARGET NAI Glenn J. Hanna marketed capsid-binding antiviral norovirus capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (capsid-binding antiviral class)

  1. Glenn J. Hanna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NAI — Competitive Intelligence Brief. https://druglandscape.com/ci/nai. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: